• Dosage of Medroxyprogesterone in details
• Medroxyprogesterone interactions
• Medroxyprogesterone reviews

Dosage of Medroxyprogesterone in details

Medroxyprogesterone Dosage

Generic name: Medroxyprogesterone 2.5mg

Dosage form: tablet

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Secondary Amenorrhea

Medroxyprogesterone tablets may be given in dosages of 5 or 10 mg daily for 5 to 10 days. A dose for inducing an optimum secretory transformation of an endometrium that has been adequately primed with either endogenous or exogenous estrogen is 10 mg of Medroxyprogesterone daily for 10 days. In cases of secondary amenorrhea, therapy may be started at any time. Progestin withdrawal bleeding usually occurs within three to seven days after discontinuing Medroxyprogesterone therapy.

Abnormal Uterine Bleeding Due to Hormonal Imbalance in the Absence of Organic Pathology

Beginning on the calculated 16th or 21st day of the menstrual cycle, 5 or 10 mg of Medroxyprogesterone may be given daily for 5 to 10 days. To produce an optimum secretory transformation of an endometrium that has been adequately primed with either endogenous or exogenous estrogen, 10 mg of Medroxyprogesterone daily for 10 days beginning on the 16th day of the cycle is suggested. Progestin withdrawal bleeding usually occurs within three to seven days after discontinuing therapy with Medroxyprogesterone. Patients with a past history of recurrent episodes of abnormal uterine bleeding may benefit from planned menstrual cycling with Medroxyprogesterone.

Reduction of Endometrial Hyperplasia in Postmenopausal Women Receiving Daily 0.625 mg Conjugated Estrogens

When estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be initiated to reduce the risk of endometrial cancer. A woman without a uterus does not need progestin. Use of estrogen, alone or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Patients should be re-evaluated periodically as clinically appropriate (for example, 3 to 6 month intervals) to determine if treatment is still necessary. For women who have a uterus, adequate diagnostic measures, such as endometrial sampling, when indicated, should be undertaken to rule out malignancy in cases of undiagnosed persistent or recurring abnormal vaginal bleeding.

Medroxyprogesterone tablets may be given in dosages of 5 or 10 mg daily for 12 to 14 consecutive days per month, in postmenopausal women receiving daily 0.625 mg conjugated estrogens, either beginning on the 1st day of the cycle or the 16th day of the cycle.

Patients should be started at the lowest dose.

The lowest effective dose of Medroxyprogesterone has not been determined.

More about Medroxyprogesterone (Medroxyprogesterone)

• Side Effects
• During Pregnancy or Breastfeeding
• Dosage Information
• Drug Images
• Drug Interactions
• Support Group
• Pricing & Coupons
• En Espanol
• 83 Reviews - Add your own review/rating
• Generic Availability

Consumer resources

• Medroxyprogesterone
• Medroxyprogesterone

  Oral (Advanced Reading)

Professional resources

• Medroxyprogesterone (FDA)
• Medroxyprogesterone (AHFS Monograph)

Other formulations

• Depo-Medroxyprogesterone
• Depo-Medroxyprogesterone Contraceptive
• depo-subQ Medroxyprogesterone 104

Related treatment guides

• Abnormal Uterine Bleeding
• Amenorrhea
• Endometrial Hyperplasia, Prophylaxis
• Birth Control
• Endometrial Cancer
• More (2) »

What other drugs will affect Medroxyprogesterone?

Tell your doctor about all your current medicines and any you start or stop using, especially:

• bosentan;

• griseofulvin;

• St. John's wort;

• an antibiotic or antifungal medicine;

• HIV or AIDS medicine;

• seizure medicine; or

• sleep medicine (to treat insomnia).

This list is not complete. Other drugs may interact with Medroxyprogesterone, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.

Medroxyprogesterone interactions

Aminoglutethimide administered concomitantly with DEPO-Medroxyprogesterone Sterile Aqueous Suspension may significantly depress the serum concentrations of Medroxyprogesterone. DEPO-Medroxyprogesterone users should be warned of the possibility of decreased efficacy with the use of this or any related drugs.

In vitro

Medroxyprogesterone is metabolized primarily by hydroxylation via the CYP3A4. Though no formal drug interaction trials have been conducted, concomitant administration of strong CYP3A inhibitors is expected to increase concentrations of Medroxyprogesterone, whereas the concomitant administration of strong CYP3A inducers is expected to decrease Medroxyprogesterone concentrations. Therefore, coadministration with strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) or strong CYP3A inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. John's Wort) should be avoided.

Laboratory Test Interactions

The pathologist should be advised of progestin therapy when relevant specimens are submitted. The following laboratory tests may be affected by progestins including DEPOPROVERA Sterile Aqueous Suspension:

1. Plasma and urinary steroid levels are decreased (e.g. progesterone, estradiol, pregnanediol, testosterone, cortisol).
2. Gonadotropin levels are decreased.
3. Sex-hormone binding globulin concentrations are decreased.
4. Protein bound iodine and butanol extractable protein bound iodine may increase. T3 uptake values may decrease.
5. Coagulation test values for prothrombin (Factor II), and Factors VII, VIII, IX, and X may increase.
6. Sulfobromophthalein and other liver function test values may be increased.
7. The effects of Medroxyprogesterone on lipid metabolism are inconsistent. Both increases and decreases in total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol have been observed in studies.

References

1. DailyMed. "MEDROXYPROGESTERONE ACETATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
2. FDA/SPL Indexing Data. "C2QI4IOI2G: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
3. MeSH. "Contraceptive Agents, Female". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Medroxyprogesterone are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Medroxyprogesterone. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 25 here

Information checked by Dr. Sachin Kumar, MD Pharmacology